Colorized scanning electron micrographs of natural killer cells from a human donor (Images: NIH / Graphics: Shehla Shakoor, Endpoints News)
November 12, 2019 03:22 PM ESTUpdated November 13, 10:23 AM
R&D

Kiadis aban­dons lead PhI­II pro­gram, shifts fo­cus to nat­ur­al killer cells

Jason Mast

Editor

Kiadis Phar­ma an­nounced that it is shift­ing fo­cus to nat­ur­al killer cells — and is it­self killing off the long-run­ning but deeply trou­bled Phase III ATIR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times